Insulet Corporation ($PODD) Stock Forecast: Up 5.4% Today

What is Insulet Corporation?

Insulet Corporation (NASDAQ: PODD) is a company known for its Omnipod tubeless insulin delivery systems. Today, the stock had a strong bullish movement in the market.

Why is Insulet Corporation going up?

PODD stock is up 5.4% on Apr 30, 2026 18:11

• The bullish movement in Insulet's stock today could be attributed to a disclosure of a significant stake by Vanguard, indicating confidence from a major investment firm.
• Additionally, the anticipation surrounding Insulet's first-quarter earnings release might have fueled investor optimism, especially considering the company's focus on diabetes technology aligning with the current healthcare trends.
• Despite the positive factors, it's essential to note that the stock experienced a significant drop recently, possibly due to concerns raised by the clarification regarding Serious Adverse Events versus FDA device reports, which could have initially impacted investor sentiment negatively.
• Overall, the combination of positive investment news, upcoming earnings release, and recent market fluctuations likely contributed to the bullish movement in Insulet's stock today.

PODD Price Chart

PODD Technical Analysis

PODD News

Vanguard discloses 5.28M-share stake in Insulet (NASDAQ: PODD)

Vanguard Capital Management has reported a beneficial ownership of 5,277,842 shares, representing a 7.49% stake in Insulet Corp (NASDAQ: PODD), as detailed in a recent Schedule 13G SEC filing. The filing, signed by Ashley Grim on April 30, 2026, indicates Vanguard holds sole dispositive power over all these shares and sole voting power over 698,568 shares, reflecting a passive investment. This disclosure is based on ownership as of March 31, 2026.

https://www.stocktitan.net/sec-filings/PODD/schedule-13g-insulet-corp-passive-investment-disclosure-5-99a0c71e9046.html

Insulet Stock (US45784P1012): Earnings Release Scheduled for Today

Insulet Corporation (US45784P1012), known for its Omnipod tubeless insulin delivery systems, is scheduled to release its first-quarter 2026 earnings today, April 30, 2026. Investors are keen to see the company's performance amid a robust U.S. market and will focus on demand for Omnipod products and updates to fiscal 2026 guidance, while also considering risks like reimbursement pressures and supply chain issues. The company's focus on diabetes tech aligns with growing U.S. healthcare spending on chronic disease management.

https://www.ad-hoc-news.de/boerse/news/ueberblick/insulet-stock-us45784p1012-earnings-release-scheduled-for-today/69263391

Mizuho cuts GE HealthCare stock price target on macro concerns

Mizuho has reduced its price target for GE HealthCare (NASDAQ:GEHC) shares from $90 to $80, while maintaining an Outperform rating, citing macro concerns despite the stock appearing undervalued at current levels. The company reiterated its organic revenue growth guidance of 3% to 4% and adjusted its EPS outlook to $4.80-$5.00, factoring in slight second-half improvements. Recent hospital capital surveys show stable demand for imaging equipment, and GE HealthCare is exploring options for its PCS segment and pursuing tariff reimbursement for cash upside.

https://www.investing.com/news/analyst-ratings/mizuho-cuts-ge-healthcare-stock-price-target-on-macro-concerns-93CH-4647053

Insulet (PODD) explains 29 serious events vs 476 FDA device reports

Insulet Corporation has issued a clarification regarding its voluntary Medical Device Correction, distinguishing between confirmed Serious Adverse Events and broader Medical Device Reports. The company confirmed 29 Serious Adverse Events, contrasting with the FDA's reference to 476 Medical Device Reports as potentially related to the correction. Insulet also stated that the inclusion of 13 expired lots in its communication does not alter its previously communicated estimated financial impact.

https://www.stocktitan.net/sec-filings/PODD/8-k-insulet-corp-reports-material-event-dd174243463e.html

Insulet Down Over 11%, On Pace for Largest Percent Decrease Since May 2020 -- Data Talk

Insulet Corporation (PODD) stock is down over 11% today, marking its largest percentage decrease since May 2020. This significant drop follows a previous decline yesterday and positions the company for notable losses. The data suggests a negative market reaction to current developments concerning the company.

https://news.futunn.com/en/post/72319750/insulet-down-over-11-on-pace-for-largest-percent-decrease

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

Insulet Corporation Price History

30.03.2026 - PODD Stock was up 5.4%

• The bullish movement in Insulet's stock today could be attributed to a disclosure of a significant stake by Vanguard, indicating confidence from a major investment firm.
• Additionally, the anticipation surrounding Insulet's first-quarter earnings release might have fueled investor optimism, especially considering the company's focus on diabetes technology aligning with the current healthcare trends.
• Despite the positive factors, it's essential to note that the stock experienced a significant drop recently, possibly due to concerns raised by the clarification regarding Serious Adverse Events versus FDA device reports, which could have initially impacted investor sentiment negatively.
• Overall, the combination of positive investment news, upcoming earnings release, and recent market fluctuations likely contributed to the bullish movement in Insulet's stock today.

20.01.2026 - PODD Stock was down 5.8%

• Insulet Corporation (PODD) witnessed a downturn in its stock, despite strong Q4 results and an expansion of its share repurchase program.
• The stock's decline may be linked to JPMorgan Chase & Co. revising Insulet's price target downward from $415.00 to $340.00 due to cautious guidance, despite robust earnings and revenue growth.
• Other factors contributing to the bearish movement include concerns about the company's valuation, competitive landscape in the diabetes market, and technical challenges like trading below its moving averages.
• The market sentiment appears mixed, with positive financial performance offset by underlying uncertainties, resulting in selling pressure on the stock.

19.01.2026 - PODD Stock was down 5.6%

• Despite a strong Q4 performance showing a 31% revenue growth and surpassing earnings expectations, Insulet's stock (PODD) faced a 5.6% decline.
• The market response was negative due to Insulet's conservative short-term outlook, which overshadowed its solid financial results and expansion initiatives.
• A reduction in price target by a major financial institution from $415.00 to $340.00, though still affirming an "overweight" rating, added to the stock's downward trend.
• Investor apprehension regarding the potential effects of the cautious guidance on Insulet's future growth trajectory likely contributed to the stock's decline, despite the positive earnings outcome.

19.01.2026 - PODD Stock was down 6.8%

• A significant number of shares of Insulet Corporation were acquired by Cumberland Partners Ltd, indicating confidence in the company's future prospects.
• Insulet's stock price target was lowered by Canaccord Genuity due to valuation concerns, despite the company reporting strong Q4 earnings and revenue growth.
• Impressive financial results for Q4 and full year 2025 were reported by Insulet, showing consistent revenue growth and strategic developments in the diabetes management market.
• The market may have reacted bearishly to the lowered price target by Canaccord Genuity, overshadowing the positive earnings and growth reported by Insulet.

19.01.2026 - PODD Stock was down 6.0%

• In recent quarters, Insulet Corporation recorded strong Q4 earnings and revenue surpassing expectations. Despite the impressive growth in Omnipod revenues and a positive outlook, the company's stock saw a decline.
• One factor contributing to the stock's downturn is a decrease in Insulet's stock price target by Canaccord Genuity. This adjustment reflects industry valuation compression, despite the strong financial performance of the company.
• The purchase of shares by Cumberland Partners Ltd and other institutional investors initially instilled confidence in the stock but was insufficient to counter the prevailing market sentiment.
• Following Insulet's mention of challenging year-over-year comparisons, investors engaged in profit-taking, resulting in a bearish trend in the stock price.

30.03.2026 - PODD Stock was down 7.3%

• Insulet Corporation's stock (PODD) dropped by over 11%, marking its largest decline since May 2020, reflecting strong bearish sentiment.
• The market's negative response may stem from Insulet's clarification on Serious Adverse Events, differing from the FDA's reports, causing investor concerns.
• Sector-wide selling in the medical devices industry affected companies like GE HealthCare Technologies and DexCom, contributing to the downturn in Insulet's stock.
• Despite Mizuho's reduced price target for GE HealthCare shares due to macro concerns, steady demand for imaging equipment and GE HealthCare's pursuit of tariff reimbursement might have diverted investors' focus from Insulet, leading to PODD stock's bearish movement.

18.01.2026 - PODD Stock was up 5.3%

• Insulet (PODD) shares rose by 5.6% post the disclosure of robust fourth-quarter financial results that surpassed expectations, attributed to heightened demand for its Omnipod insulin management systems.
• The company's positive projection of a 26% year-over-year sales upsurge for the first quarter of 2026 added to the stock's upward momentum.
• Despite a previous decline of 7.9% since the year's commencement, the recent favorable performance suggests that investors may have found confidence in the company's financial strength and strategic initiatives.
• Insulet's focus on innovation, market expansion, and precise execution in transforming diabetes care likely fostered investor trust, fueling the notable increase in the stock price.

13.02.2026 - PODD Stock was down 5.2%

• The decline in Insulet's stock (PODD) today is tied to a voluntary correction made by the company concerning specific lots of Omnipod 5 Pods due to a manufacturing problem causing insulin leaks. This has raised concerns about product safety and potential revenue impact.
• Negative information about the insulin leak issue may have overshadowed favorable study results released by Insulet Corporation on a fully closed-loop automated insulin delivery system, which demonstrated promising outcomes for adults with type 2 diabetes. However, the recall news appears to have had a more immediate effect on investor sentiment.
• Furthermore, the decrease in Swiss National Bank holdings may have intensified selling pressure on the stock, suggesting a lack of short-term confidence from institutional investors.
• Despite recent challenges, Insulet's solid Q1 earnings and positive analyst outlook, with a target price of $354.24, suggest favorable long-term growth potential for the company, contingent on resolving the current manufacturing problem and successfully launching their innovative products.

13.02.2026 - PODD Stock was down 7.1%

• Insulet Corporation's stock (PODD) experienced a significant bearish movement following the announcement of a voluntary recall of specific Omnipod 5 Pods due to a risk of internal leaks, leading to under-delivery of insulin and causing serious adverse events, including hospitalizations and diabetic ketoacidosis.
• The recall of defective Omnipod insulin delivery devices has raised concerns among investors, leading to a negative impact on Insulet's stock price.
• The anticipated recall-related costs of up to $40 million for 2026 have also contributed to the bearish sentiment surrounding Insulet Corporation.
• The analysis of Insulet's valuation, indicating undervaluation based on Discounted Cash Flow (DCF) model but overvaluation based on Price-to-Earnings (P/E) ratio, further adds to the uncertainty and downward pressure on the stock price.

13.02.2026 - PODD Stock was down 7.7%

• The bearish movement in Insulet Corporation's stock (PODD) today can be attributed to the following factors:
• The recall of specific lots of Omnipod 5 insulin patch pumps due to a manufacturing issue leading to insulin leakage and serious adverse events like hospitalizations and diabetic ketoacidosis has raised concerns among investors about product safety and potential financial implications.
• The analysis of Insulet's valuation, indicating that the stock may be overvalued based on Price-to-Earnings ratio compared to industry averages, could have prompted profit-taking and selling pressure.
• The reduction in holdings by the Swiss National Bank may have also contributed to the negative sentiment surrounding the stock, signaling reduced institutional confidence in the company's future prospects.
• Despite the recall and valuation concerns, Insulet's strong Q1 earnings performance and analyst recommendations for the stock indicate a mixed outlook, with investors likely monitoring developments closely before making investment decisions.

29.03.2026 - PODD Stock was down 9.4%

• Insulet Corporation's stock hit a 52-week low due to a challenging year marked by a 29.13% decline, driven by competitive pressures and a voluntary recall of some Omnipod 5 insulin pumps. This negative sentiment was further exacerbated by analyst ratings being adjusted downwards.
• The stock underperformed compared to competitors for the fourth consecutive day, reflecting broader market trends where the S&P 500 Index and Dow Jones Industrial Average also experienced declines. This consistent underperformance indicates ongoing struggles for Insulet Corp.
• Despite participating in the BofA Securities 2026 Health Care Conference to showcase its innovative solutions for diabetes management, including the Omnipod brand, investors remain cautious due to the company hitting new 52-week lows and facing challenges in profitability.
• The stock's recent decline to USD 186.25, significantly below its high of USD 354.88, underscores investors' concerns about the company's financial performance despite strong long-term sales growth. High institutional holdings indicate continued scrutiny on the stock's performance amidst its struggles.

29.03.2026 - PODD Stock was down 5.1%

• The stock decreased by 2.89% to $182.87, dropping to a 52-week low of $186.25, reflecting a substantial decrease from its recent peak.
• Despite participating in the BofA Securities 2026 Health Care Conference to showcase its technology and solutions, investor concerns regarding profitability, device issues, and heightened competition from GLP-1 drugs have impacted market sentiment.
• The stock's lagging performance compared to its peers and industry benchmarks, combined with a premium valuation signified by a P/E ratio of 53.1x, have raised doubts about whether the market has factored in its future growth potential.
• Investors are closely watching the company's financial results, particularly the decline in net profit and profitability challenges, amid a generally negative trading day in the market.